Form 4: Sangamo Therapeutics CEO Sells Shares for Tax Obligations Following RSU Vesting

Sangamo Therapeutics CEO, Sandy Macrae, disposed of shares to cover tax obligations following the vesting of restricted stock units.

Summary

• Sangamo Therapeutics CEO, Sandy Macrae, sold shares on November 24 and 25, 2024, to cover mandatory tax withholding obligations related to the vesting of restricted stock units (RSUs).
• On November 24, 7,473 shares were sold at $1.88 per share, and on November 25, 10,642 shares were sold at $1.94 per share.
• These transactions were not discretionary trades but were required to cover tax liabilities associated with the vesting of the RSUs.
• Following these transactions, Macrae beneficially owns 2,508,583 shares of Sangamo Therapeutics stock.
• The remaining unvested shares from the RSU grants will vest in future quarterly installments through February 2026.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation. There is no indication of positive or negative sentiment, it is a standard process.

Future Outlook

The remaining shares from the RSU grants will continue to vest in future quarterly installments through February 2026, subject to the CEO's continuous service.

Industry Context

This is a routine transaction for executives who receive equity compensation. It is common for shares to be sold to cover tax obligations upon vesting of RSUs.

Comparison to Industry Standards

• The practice of selling shares to cover tax obligations upon RSU vesting is standard across publicly traded companies.
• Many companies use similar equity incentive plans to compensate executives, and these plans often include provisions for tax withholding.
• The number of shares sold and the price per share are consistent with the company's stock performance and the terms of the RSU grants.

Stakeholder Impact

• The share disposals are unlikely to have a significant impact on shareholders as they are routine transactions for tax purposes.
• The transactions do not indicate any change in the CEO's commitment to the company.

Key Dates

Keywords

Sangamo Therapeutics, Sandy Macrae, RSU, restricted stock units, tax withholding, share disposal, insider trading, equity compensation